Collaborative Arrangements (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Aug. 03, 2015	Feb. 01, 2012	Jul. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
GlaxoSmithKline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received			$ 6,000,000
Revenue recognized				$ 6,500,000		$ 5,000,000
Term of milestone agreement			3 years
Contingent payment, completion of milestones and agreement			$ 7,500,000
Minimum milestone receivable			5,750,000.00
Maximum milestone receivable			$ 38,500,000.0
License extension acceptance period			3 years
Termination notice period			90 days
License and services revenue				500,000			$ 1,500,000	$ 451,613
Deferred Revenue				3,500,000		5,000,000	3,500,000
Technology Transfer, Collaboration and License Agreement [Member] | Merck [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received	$ 5,000,000
Revenue recognized				5,000,000
Contingent payment, completion of milestones and agreement	8,000,000
Potential royalty revenue	$ 15,000,000
Termination notice period	90 days
License and services revenue				400,000
Deferred Revenue				4,600,000			4,600,000
Upfront License fee, period for recognition	2 years
Contingent termination revenue	$ 8,000,000
Supply Agreement [Member] | Merck [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and services revenue				500,000	$ 500,000		1,500,000	$ 1,500,000
Deferred Revenue				$ 1,400,000		$ 900,000	$ 1,400,000
Term of collaborative research and development agreement (years)		5 years